poisar

Stocks · News reference

Eli Lilly Licenses SpeechDx Dataset for Alzheimer's Research

Eli Lilly and Company has entered a collaboration with the Alzheimer's Drug Discovery Foundation to license the SpeechDx dataset for use in Alzheimer's disease research.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LLY
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

    The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

    ABBVLLYJNJNVSBMY